Reungwetwattana T, et al. - In patients with untreated epidermal growth factor receptor (EGFR)-mutated advanced non–small-cell lung cancer from the phase III FLAURA study, researchers reported CNS efficacy of osimertinib vs standard EGFR tyrosine kinase inhibitors (TKIs). In the study, 556 patients were randomly assigned to osimertinib or standard EGFR-TKIs (gefitinib or erlotinib). In patients with untreated EGFR-mutated non–small-cell lung cancer, osimertinib was seen to have CNS efficacy. Compared to standard EGFR-TKIs, osimertinib showed a reduced risk of CNS progression.